The most common organ-specific autoimmune disease in humans involves the thyroid. Autoantibodies against thyroid peroxidase (TPO) are present in the sera of virtually all patients with active disease. We report the molecular cloning of the genes for 30 high-affinity, IgG-class human autoantibodies to TPO from thyroid-infiltrating B cells. Analysis of the putative germline genes used for the TPO human autoantibodies suggests the use of only five different H and L chain combinations involving four H chains and three L chains. In addition, the same combination of H and L chains was found in multiple patients. The F(ab) proteins expressed by these genes define two major, closely associated domains (A and B) in an immunodominant region on TPO. These A and B domains contain the binding sites of 80% of IgG-class TPO autoantibodies in the sera of patients with autoimmune thyroid disease. The present information permits analysis, not previously possible, of the relationship between autoantibody H and L chain genes and the antigenic domains on an autoantigen. Our data, obtained using target organ-derived autoantibodies, indicate that there is restriction in H and L chain usage in relation to the interaction with specific antigenic domains in human, organ-specific autoimmune disease. (J. Clin. Invest. 1993. 92:62-74.)
Introduction
The most common organ-specific autoimmune disease in humans involves the thyroid. Hashimoto's thyroiditis and Graves' disease, in their pure forms, represent two ends of a clinical spectrum ranging from glandular hypofunction to hyperfunction. In both diseases there is a breakdown in tolerance to a number of thyroid-specific autoantigens and the generation ofan IgG antibody response. Thyrotropin receptor autoantibodies occur predominantly in Graves' disease and are responsible for hyperthyroidism (reviewed in reference 1). Autoantibodies to thyroglobulin, of uncertain pathogenetic importance, tend to be found in patients with Hashimoto's thyroiditis rather than Graves' disease. However, autoantibod-ies against thyroid peroxidase (TPO),' the cell surface enzyme responsible for thyroid hormone synthesis and previously known as the thyroid "microsomal" antigen, are present in virtually all patients with active autoimmune thyroid disease (2, 3) .
TPO autoantibodies are of high affinity and predominantly IgGl and IgG4 (4) . There is evidence that these IgGl (but not IgG4) autoantibodies may play a role in thyroid cell destruction (reviewed in reference 5). TPO autoantibodies correlate well with thyroid inflammation in autopsy studies of subjects without clinical thyroid disease (6) . With newer, sensitive assays, TPO autoantibodies (of unknown affinity) are detectable, usually at low levels, in up to 25% of the adult female population (7) . The present concept is that autoimmune thyroid disease is predominantly subclinical because of sufficient thyroid reserve and regeneration under the influence of thyrotropin.
Information on the genes coding for organ-specific autoantibodies, as well as knowledge oftheir epitopes, would be invaluable in understanding the pathogenesis of antibody-mediated autoimmune diseases. Among the major organ-specific human autoimmune diseases (thyroiditis, diabetes mellitus type I, pemphigus vulgaris, myasthenia gravis, primary biliary cirrhosis, pernicious anemia, and Addison's disease), few IgG class monoclonal autoantibodies have been produced and even fewer cloned at the molecular level (8) (9) (10) (11) (12) . In no disease have both the autoantibody repertoire and the autoantigenic domains been defined.
We now report the molecular cloning of the genes for 30 new organ-specific (TPO) human autoantibodies. These genes all code for high-affinity IgG autoantibodies. We demonstrate that these TPO autoantibodies, which appear to utilize a restricted number ofH and L chain genes, encompass a restricted immunodominant region on TPO recognized by patients with autoimmune thyroid disease.
Methods
Molecular cloning ofTPO-binding F(ab)fragments. In order to obtain TPO-binding F(ab)s we used thyroid tissue from patients with autoimmune thyroid disease because it is enriched, compared with blood, lymph node, and thymus, in B cells secreting TPO autoantibodies (reviewed in reference 13). In addition, previous studies have demonstrated the difficulty ofobtaining thyroid-specific monoclonal autoantibodies, particularly TPO autoantibodies, by using blood versus thyroid lymphocytes ( 14) .
We constructed five new human F(ab) combinatorial cDNA libraries from the thyroid tissue ofthree patients (WR, TR, and JA) with Graves' disease in the vector Immunozap (Stratacyte, La Jolla, CA) as described previously (10) , with the following modifications. We pre- G--------------G-------- (16) VH3;plusothers (C ----------G C----------) VH 1/5BACK (17) VH1; VH5 (G----------G C--G-----GG)
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VK3a ( (21) . TPO-binding plaques were cloned to homogeneity and plasmids were excised from the Immunozap bacteriophage using the helper phage R408, according to the Stratacyte protocol. Nucleotide sequencing ofthe cDNA inserts was performed by the dideoxynucleotide chain termination method (22) . Preparation ofsoluble F(ab) fragments. F(ab)s were expressed as soluble proteins in XLl-Blue cells, as previously described (1 ) . In brief, protein synthesis was induced with 1 mM isopropyl-thio-galactopyranoside (Sigma Chemical Co., St. Louis, MO) for 2 h at 37°C. The cells were then pelleted, resuspended in 0.02 times the original volume of 10 mM Tris, pH 8.0, containing 2,ug/ml aprotinin, 1 1tg/ml leupeptin, 1 ug/ml pepstatin, 0.1 mM phenylmethylsulfonyl fluoride (all from Sigma Chemical Co.). After one freeze-thaw, the suspension was sonicated, membranes pelleted by centrifugation at 4,000 g and the F(ab)s were affinity-purified from the supernatant using a Protein G sepharose column (Pharmacia, Inc.).
Direct F(ab) binding of'25I-TPO. As previously described (11), F(ab)s diluted in assay buffer (0.1 M NaCl, 10 mM Tris-HC1, pH 7.5, 0.1% Tween 20, and 0.5% BSA) were incubated with '25I-TPO (15, volume of 200 Ml. After 1 h at room temperature, 100 AI of donkey anti-mouse Sac-cel (IDS, Boldon, Tyne and Wear, UK) was added, and the incubation was continued for 30 min. After addition of 1 ml of assay buffer and vortexing, the mixture was centrifuged for 5 min at 1,000 g to sediment the immune complexes which were then counted to determine the percent radiolabeled TPO bound. The affinities ofthe F(ab)s for TPO were determined by Scatchard analysis (23) from values obtained in the presence of increasing concentrations of unlabeled TPO.
Competition between F(ab)s for binding to TPO. One F(ab) was immobilized by incubation (total volume of200 Al) with murine mAb anti-human K (QEl 1) for 1 h at room temperature. After incubation with 100 ,l of Sac-cel (30 min at room temperature), the immobilized F(ab) complexes were diluted in assay buffer (see above) and centrifuged at 1,000 g (5 min at 4°C). The pellets were resuspended in normal human serum diluted 1:30 in assay buffer to saturate remaining anti-K binding sites. In a separate set of tubes, increasing concentrations of "free" F(ab) were preincubated with 125I-TPO for 1 h at room temperature. Aliquots (100 Ml) were then incubated for 30 min with the immobilized F(ab) pellets and washed with assay buffer, and the radioactivity bound to the Sac-cel was counted. Nonspecific binding (-2% of total counts added) was subtracted to provide values for specific binding to TPO.
Competition studies between F(ab)fragments andserum TPO autoantibodies. Sera from 10 patients with autoimmune thyroid disease were studied. All sera contained high levels of TPO autoantibodies (detectable by ELISA [24] (10, 11, 26) were compared to the closest, presently known germline genes. It must be emphasized that, even with the recent expansion of VH germline sequence information (27) , the germline assignments are putative and cannot be regarded as definitive without characterization of the respective genes in these patients. Homologies are shown simply as a means to categorize the large body of data.
The 34 TPO human autoantibodies appeared to use a relatively restricted number and combination of H and L chain genes (Figs. 2-5, summarized in Table II ). In particular, L chain putative germline gene KLO12 (28), a VK1, is used in TPO autoantibodies from all four patients (Figs. 2 and 4). In three patients, KLO 12 was the only L chain obtained. However, for this very large group of L chains, the possibility of other germline gene usage cannot be excluded. Indeed the nucleotide sequence pattern (Fig. 2 ) of the WR4 L chains differs from those of the other KLO 12-related L chains. In one patient (TR), two other TPO-specific L chains were obtained; A' (29) is a VK1 (like KL012) and A3 (29) is a VK2.
The TPO-specific F(ab) H usage appears to be slightly less restricted than that of the L chain (Figs. 3 and 5, summarized in Table II (Fig. 6 A) , TR1.8 and TRl .9 each completely inhibited TPO binding to immobilized TR 1.9. In contrast, preincubation of WR1.7 and SP1.5 with radiolabeled TPO did not prevent subsequent TPO binding to immobilized TRl .9. Despite these differences in their ability to compete for TPO binding to TR 1.9, allfree F(ab)s were capable ofbinding comparable amounts ofradiolabeled TPO in separate, concurrent direct binding assays (Fig. 6 B) .
The above experiment (Fig. 6, A (27) . (Fig. 6 C) . The SP1.5 binding domain overlapped that of TR1.3 and WR1.7 but not TRl.9 (Fig. 6 D) . The SP1.5 domain appeared to overlap to a small extent with that of TR1.8 (Fig. 6 D) . It is important to note that these differences between F(ab) binding domains are not related to differences in their affinities for TPO (Table III) . A spectrum of competition patterns was observed in 10 randomly selected sera of patients with autoimmune thyroid disease. In the representative examples shown, TPO autoantibodies in patients' sera were inhibited preferentially by WR 1. oligonucleotide primers (see Table I ). ( Fig. 8 A) , preferentially by TR1.9 ( Fig. 8 B) or in a more balanced proportion by both F(ab)s (Fig. 8 C) . Overall, ofthe 10 sera, five were inhibited preferentially by WRl.7, two by TR 1.9, and three to approximately the same extent by WR1.7
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and TRl.9. Of greater importance was the efficacy of the combination of the WRI.7 and TRl.9 F(ab)s in competing for serum TPO autoantibody binding. In the 10 sera, this combination inhibited TPO autoantibody binding by 83±5% (mean±SEM). These figures may underestimate the full extent of the inhibition because of limitations to the highest concentrations of F(ab)s which could be used for competition.
Discussion
There is evidence that the ability to produce TPO autoantibodies is inherited as an autosomal dominant trait in women with incomplete penetrance in men (34, 35) . The location and nature of the gene or gene cluster responsible for this inheritance are unknown. Polymorphisms at the VH locus are associated with autoantibody production (31, 36) . Therefore, knowledge of the genetic background of TPO-specific autoantibodies may provide insight into the basis for the inheritance of thyroid autoimmunity.
The present report identifies and characterizes the genes coding for a comprehensive panel of high-affinity human autoantibodies to a major, organ-specific autoantigen. These recombinant F(ab)s cover a region on thyroid peroxidase recognized by a majority ( -80%) ofautoantibodies in the sera ofpatients with thyroiditis, the most common autoimmune disease. In the more intensively studied connective tissue diseases, genes for numerous autoantibodies have been characterized. Initially, the "natural" and disease-associated autoantibodies cloned were IgM, many of low affinity and with polyspecificity (37, 70 Chazenbalk et al. (39) (40) (41) (42) . However, the combination of a comprehensive autoantibody repertoire and its antigenic domain(s) has not been defined previously in either organ-specific or nonorgan-specific autoimmune disease in humans.
From thyroid tissue-infiltrating B cells from three patients with autoimmune thyroiditis, we have cloned and determined the nucleotide sequences of30 new TPO-specific F(ab)s. Previously, we had reported information on four antibodies obtained from another patient ( 10, 1 1, 26) . The most remarkable finding from analysis of the putative germline genes used for TPO human autoantibodies is the relatively restricted number and combinations of H and L chain genes. Similarly, there is evidence for restricted T cell receptor V gene usage in the early stages of autoimmune thyroid disease (reviewed in reference 43). In our study of 34 recombinant F(ab)s, we found a total of only five different H and L chain combinations involving four H chains and three L chains. In addition, one combination of H and L chains (HV ILl and KLO 12) was obtained (38, 44) . In contrast, four-fifths ofour TPO-specific F(ab) combinations were derived from VHl family germline genes. The other F(ab) utilized a VH3 germline gene. Among the VHl-encoded TPO F(ab)s, the most abundant were related to the recently described HV1LI germline gene, which is utilized in a rheumatoid factor (30). Because of the pattern of nucleotide differences between our TPO F(ab)s and HViLi, it is possible that the former are not derived from HVILl but from another, as yet undescribed, germline gene.
Three Figure 8 . Domains on TPO recognized by autoantibodies in three representative sera (panels A, B, and C) from patients with autoimmune thyroid disease. F(ab)s WRI.7 and TRI.9, alone or in combination, were used to compete for serum autoantibody binding to radiolabeled TPO (Methods).
cover all six VH families (Table I ). In addition, the F(ab)s obtained used variable regions genes from more than one VH (VH 1, VH3) and VK (VK1, VK2) family. Our libraries also contain VH4 genes as we obtained this family in a F(ab), the sequence of which is not included in the results because we could not express the protein.
We have evidence against the possibility ofover-representation in our libraries ofparticular VH and VL genes. In separate studies (26) , we observed that functional HV LI VH and KL012 VL genes in a library are relatively rare, -1:5,000 and 1:500, respectively. Finally, the most important evidence suggesting that the TPO-specific VH and VL gene restriction observed is not a consequence of all three potential limitations discussed above is that the F(ab)s expressed in our repertoire represent more than 80% of TPO autoantibodies present in patients' sera.
Whether or not the combinatorial library approach can generate the H and L chain combinations observed in vivo is under debate (46, 47) . The same pairing of H and L chains was observed in murine monoclonal antibodies (specific for influenza hemagglutinin) generated by both conventional hybridoma technology and the combinatorial recombinant F(ab) approach (48) . In contrast, in a study ofhapten antibodies, the in vivo H and L chain pairing was not attained by the combinatorial approach (46) . In addition, some studies have shown H chain promiscuity in pairing with L chains (47) . Therefore, we cannot be certain that the TPO-specific H and L chain combinations reflect the in vivo situation. However, using a TPOspecific H (or L) chain to randomly search for other L (or H chains) from the same patient capable of forming F(ab)s with high affinity for TPO, we did not observe promiscuity and only obtained closely related L and H chains from the same VK and VH families (26) . Further, our F(ab)s had very high affinities for TPO (-10-10 M), comparable with those of serum TPO autoantibodies (2) .
Turning to the other major aspect of our study, the majority of TPO subsequently for an affinity-matured IgG molecule (42 (62) . A possible explanation for these divergent observations is that the autoantibodies are interacting with a wide range of epitopes. For example, thyroglobulin autoantibodies, induced by immunization in mice, interact with many epitopes and are derived from a large number of V region gene segments (63) . In contrast, our data in an organ-specific autoimmune disease, indicate that diseaseassociated autoantibodies recognize a limited antigenic region on TPO. Such autoantibodies do, indeed, appear to be associated with restricted H and L chain usage.
